Global Rheumatoid Arthritis Market Report: 2016 Edition
Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.
Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.
The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.
The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.
The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.